Form 4: BioRestorative Therapies CEO Lance Alstodt Reports Stock Option Grant
SEC Filing
Lance Alstodt, CEO of BioRestorative Therapies, reports the acquisition of stock options.
Summary
- On February 18, 2025, Lance Alstodt, the President, CEO, and Chairman of the Board of BioRestorative Therapies, Inc., filed a Form 4.
- The filing reports a transaction on February 14, 2025, where Alstodt acquired 791,885 stock options with an exercise price of $2.46.
- These options vest in installments starting February 14, 2025.
- Alstodt directly owns 171,872 shares of common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The stock option grant is a standard compensation practice.
Positives
- The grant of stock options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
This filing is a routine disclosure related to executive compensation and is typical for publicly traded companies.
Comparison to Industry Standards
- Stock option grants are a common form of executive compensation in the biotechnology industry.
- Vesting schedules are designed to align executive incentives with long-term company performance, which is a standard practice.
Stakeholder Impact
- The stock option grant could potentially motivate the CEO to improve company performance, benefiting shareholders.
- The grant has no immediate impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 02/17/2023 | 53,381 shares of stock options with exercise price of $2.91 vest. |
| 02/13/2024 | 219,298 shares of stock options with exercise price of $1.45 vest. |
| 02/14/2025 | Date of stock option grant and vesting of 395,943 shares of options with exercise price of $2.46. |
| 02/18/2025 | Date of Form 4 filing. |
| 03/18/2031 | Expiration date for stock options with exercise price of $5.08. |
| 11/04/2031 | Expiration date for stock options with exercise price of $5.08. |
| 02/17/2033 | Expiration date for stock options with exercise price of $2.91. |
| 02/13/2034 | Expiration date for stock options with exercise price of $1.45. |
| 02/14/2035 | Expiration date for stock options with exercise price of $2.46. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.